MedTrace Logo

Iron in Patients With Cardiovascular Disease

NCT03991000 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-12-27

No results posted yet for this study

Summary

It is now recognized that iron deficiency in cardiovascular disease contributes to impaired clinical outcome.

Conditions

Interventions

DRUG

Ferric carboxymaltose

Intravenous iron

DRUG

Saline

Saline application according to dosing rules of iron.

Sponsors & Collaborators

  • Dr. med. Mahir Karakas

    lead OTHER

Principal Investigators

  • Mahir Karakas, MD, MBA · University Heart Center Hamburg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-28
Primary Completion
2021-12-15
Completion
2021-12-15

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03991000 on ClinicalTrials.gov